Page last updated: 2024-08-25

bendamustine hydrochloride and Lymphoma, Non-Hodgkin

bendamustine hydrochloride has been researched along with Lymphoma, Non-Hodgkin in 126 studies

Research

Studies (126)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's23 (18.25)29.6817
2010's71 (56.35)24.3611
2020's32 (25.40)2.80

Authors

AuthorsStudies
Chen, M; Hui, M1
Leslie, LA1
Ikeda, S; Koyama, D; Misawa, K; Sukegawa, M; Suzuki, M; Teshirogi, M; Tsunoda, S1
Chen, D; Chen, Y; Gao, J; Jia, Y; Tao, H; Wang, F; Wu, P; Zhou, Z1
Andriani, A; Autore, F; Cimino, G; Del Poeta, G; Ditto, C; Fresa, A; Innocenti, I; Laurenti, L; Maglione, R; Mauro, FR; Mengarelli, A; Padua, L; Papa, E; Pelliccia, S; Principe, MID; Romeo, A; Stefanizzi, C; Tafuri, A1
Belada, D; Benesova, K; Duras, J; Hanackova, V; Janikova, A; Karban, J; Mocikova, H; Obr, A; Prochazka, V; Steinerova, K; Sykorova, A; Trneny, M; Vodicka, P1
Kawasaki, N; Nishito, Y; Yoshimura, Y; Yoshiura, S1
Edina, BC; Rinaldi, I1
Frascione, PMM; Novo, M; Paruzzo, L; Poletto, S; Vitolo, U1
Kameoka, Y1
Aisa, Y; Ito, C; Kadota, S; Kurosawa, S; Nakayama, H; Nakazato, T; Okubo, S; Sakurai, A; Shinmura, K1
Cen, H; Ding, K; Gao, Y; Huang, H; Lin, J; Liu, Y; Lv, F; Ma, L; Song, B; Tang, X; Wang, S; Wang, Y; Wu, D; Wu, J; Xiang, Y; Xu, W; Yang, Y; Ye, X; Yu, H; Zhang, F; Zhang, Q; Zhao, Y; Zhou, J1
DiMaria, E; Drennan, IR; Gerard, L; Kotchetkov, R; Nay, D; Prica, A; Susman, D1
Cordoba, R; Fleury, I; Greil, R; Hess, G; Joffe, E; Kim, K; Ku, M; Kurukulasuriya, NC; Marks, R; Mondello, P; Nowakowski, GS; Peters, A; Sabatelli, L; Salles, G; Sporchia, A; Trotman, J; Waltl, EE; Winderlich, M; Yoon, DH; Zinzani, PL1
Du, KX; Li, JY; Li, Y; Liang, JH; Shen, HR; Wang, L; Wu, JZ; Xia, Y; Xu, W; Yin, H1
Aktar, SJ; Ante, Z; Chan, KKW; Cheung, MC; Liu, N; Prica, A; Suleman, A1
Kodama, Y; Miyazaki, Y; Ohtsuka, E; Saburi, M; Sakata, M; Takata, H; Urabe, S; Uraisami, K; Wada, J1
Doki, N; Haraguchi, K; Hayashi, Y; Ishimine, K; Kanemasa, Y; Kobayashi, T; Mino, M; Morita, Y; Najima, Y; Nakamura, S; Ohashi, K; Ohigashi, A; Okuya, T; Okuyama, Y; Sasaki, Y; Shimizu, H; Shimizuguchi, T; Shimoyama, T; Shingai, N; Tamura, T; Toya, T; Yagi, Y1
Jakobs, F; Kron, F; Kurte, MS; Reinhardt, HC; Siefen, AC; von Tresckow, B1
Belada, D; Cheson, BD; Fingerle-Rowson, G; Gribben, J; Harbron, C; Hoster, E; Kahl, B; Kehden, B; Mundt, K; Nicolas-Virelizier, E; Pott, C; Sehn, LH; Spielewoy, N; Wassner-Fritsch, E1
Dixon, BN; Ni, A; Sarlo, KM; Straus, DJ1
Bovo, C; Krampera, M; Quaglia, FM; Tisi, MC; Visco, C1
Cho, SH; Chung, JS; Jo, JC; Kim, DY; Shin, HJ1
Arcaini, L; Arcari, A; Bergamini, F; Bertù, L; Bianchi, B; Bolis, S; Cencini, E; Cocito, F; Defrancesco, I; Fabbri, N; Farina, L; Ferrario, A; Gentile, M; Gini, G; Goldaniga, M; Greco, A; Loseto, G; Luminari, S; Merli, M; Molinari, AL; Mora, B; Passamonti, F; Rossi, FG; Saturni, V; Scapinello, G1
Akiba, K; Hashida, T; Hirano, T; Hosohata, K; Ikesue, H; Ishikawa, T; Maegawa, N; Miyasaka, M; Mori, Y; Muroi, N; Nakamura, T; Shimomura, Y; Takano, A; Uchida, M; Yamaguchi, Y1
Alpdogan, SO; Carabasi, M; Chapman, A; DiMeglio, M; Filicko-OHara, J; Flomenberg, N; Gaballa, S; Ghimire, S; Gong, J; Martinez-Outschoorn, U; Pan, J; Porcu, P; Pro, B; Ramirez, M; Rose, L; Wagner, JL; Weiss, M1
Boyd, TE; Cannan, M; Fellague-Chebra, R; Feng, X; Kingsley, E; Lyons, RM; Moezi, M; Richards, D; Sharman, J; Shtivelband, M1
Ai, WZ; Andreadis, CB; Aoun, C; Castillo, M; Cavallone, E; Crawford, E; Fakhri, B; Kambhampati, S; Kaplan, LD; Le, D; Martinelli, M; Padilla, M; Reiner, J; Sudhindra, A; Ta, T; Tuscano, JM; Wieduwilt, MJ1
Abraham, I; Bartels, T; Kumar, A; McBride, A; Moore, L; Persky, DO1
Du, X; Han, XH; Hellriegel, E; Hong, XN; Huang, HQ; James, L; Jia, YQ; Jin, J; Ke, XY; Li, W; Liu, AC; Liu, DH; Shen, ZX; Shi, YK; Wu, DP; Wu, JQ; Xiao, XB; Xu, W; Yang, JL; Yang, SM; Zhang, LS; Zhang, MZ; Zhou, DB; Zhu, J1
Babanrao Pisal, C; Davis, J; Friedberg, JW; Izquierdo, M; Janssens, A; Keating, MM; Lasher, J; MacDonald, D; Rummel, MJ; Zaucha, JM1
Baek, GT; Brown, A; Marini, BL; Mathis, NJ; Nachar, VR; Perissinotti, AJ; Phillips, TJ; Wilcox, RA1
Bar, MH; Bartlett, NL; Cabanillas, F; Chen, Z; Cheson, BD; Dodds, AJ; Ellis, T; Friedberg, JW; Ganjoo, KN; Herst, J; Joyce, R; LaCasce, AS; Lemieux, B; Leonard, JP; Martin, P; Montgomery, PG; Pressnail, B; Rajguru, SA; Robinson, KS; Smith, MR; Szer, J; van der Jagt, RH; VanderWalde, A; Williams, M1
Anthony, SP; Chanas, B; Cheung, EM; Edenfield, WJ; Hepner, A; Mattar, B; Mutch, PJ; Smith, M1
Brown, JR; Danilov, AV; Gordon, MJ; Lewis, LD1
Aotsuka, N; Igarashi, T; Irisawa, H; Itoh, K; Masuda, S; Tsujimura, H; Tsukasaki, K; Utsu, Y; Wakita, H1
Alenxandrova, K; Arfi-Rouche, J; Bourhis, JH; Castilla-Llorente, C; Danu, A; Ghez, D; Khalife-Saleh, N; Koscielny, S; Lapierre, V; Lazarovici, J; Legoupil, C; Michot, JM; Pilorge, S; Ribrag, V; Saleh, K1
Blanco, LZ; Horowitz, JM; Kanis, MJ; Karmali, R; Lurain, JR; Peevey, J; Zielenbach, M1
Akashi, K; Hosohata, K; Ikesue, H; Kato, K; Makihara, Y; Miyamoto, T; Mori, Y; Nakamura, T; Shiratsuchi, M; Suetsugu, K; Uchida, M1
Farmakiotis, D; Freedman, A; Fung, M; Gu, X; Jacobsen, E; Koo, S; Nguyen, PL; Prestes, D1
Cragg, MS; Sopp, J1
Agarwal, S; Cordero, J; de Vos, S; Dunbar, M; Enschede, SH; Flowers, CR; Fowler, N; Kozloff, M; Nastoupil, LJ; Nolan, C; Petrich, AM; Reid, E; Ross, JA; Salem, AH; Swinnen, LJ; Verdugo, M; Wang, D; Zhou, L1
Burke, JM; Chang, J; Chen, L; Flinn, IW; Hallman, D; Hawkins, T; Issa, S; Kahl, B; Kolibaba, K; MacDonald, D; Simpson, D; Trotman, J; van der Jagt, R; Wood, P1
Blajer-Olszewska, B; Chojnacki, T; Drozd-Sokołowska, J; Długosz-Danecka, M; Hus, I; Jurczak, W; Jurczyszyn, A; Puła, B; Raźny, M; Romejko-Jarosińska, J; Taszner, M1
Bogeljić Patekar, M; Kursar, M; Mandac Rogulj, I; Milunović, V; Mišura Jakobac, K; Ostojić Kolonić, S; Perica, D; Planinc-Peraica, A1
Chen, W; Li, JJ; Sadeghi, N1
Gribben, J1
Berardi Vilei, S; Berthod, G; Caspar, C; Eckhardt, K; Fischer, N; Hitz, F; Mey, U; Pabst, T; Zucca, E1
Broome, CM; Cheson, BD; McCloskey, JK1
Ogura, M1
Brugger, W; Ghielmini, M1
Beygi, H; Engle, R; Knopf, KB; Nordstrom, BL; Sterchele, JA; Teltsch, DY1
Cordes, SF; Liang, JJ; Witzig, TE1
van der Jagt, R1
Castaigne, JG; Dewilde, S; Dunlop, W; Parker, C; Woods, B1
Butrym, A; Dmoszynska, A; Dzietczenia, J; Gorska-Kosicka, M; Grzegorz, M; Hus, I; Jawniak, D; Jedrzejczak, WW; Krawczyk-Kulis, M; Kyrcz-Krzemien, S; Lech-Maranda, E; Poplawska, L; Walewski, J; Warzocha, K; Waszczuk-Gajda, A; Wrobel, T1
Burke, JM; Chen, L; Clementi, R; Craig, M; Flinn, IW; Hallman, DM; Hawkins, TE; Hertzberg, M; Issa, S; Kahl, BS; Kolibaba, K; Kwan, YL; Macdonald, D; Munteanu, M; Simpson, D; van der Jagt, R; Wood, P1
Bond, M; Burke, JM; Darwish, M; Hellriegel, E; Ludwig, E; Munteanu, MC; Phillips, L; Robertson, P1
Baumann, FT; Bloch, W; Elter, T; Fiebig, L; Hahn, M; Hallek, M; Hülsdünker, T; Mierau, A; Reinart, N; Schenk, A; Strüder, HK; Zimmer, P1
Gil, L; Kazmierczak, M; Komarnicki, M; Kroll-Balcerzak, R1
Boehme, A; Brendel, K; Dreyling, M; Fingerle-Rowson, G; Fischer, R; Gonnermann, M; Höhler, T; Kegel, T; Kellermann, L; Nusch, A; Pönisch, W; Schmidt, C; Wendtner, C1
García Muñoz, R; Izquierdo-Gil, A; Muñoz, A; Panizo, C; Rabasa, P; Roldan-Galiacho, V1
Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A1
Chen, PM; Chiou, TJ; Hou, HA; Hsiao, LT; Kuo, CY; Liu, CY; Tien, HF; Wang, MC; Wu, JH1
Blum, KA; Byrd, JC; Christian, B; Flynn, J; Jaglowski, S; Jenkins, C; Jones, JA; Lozanski, G; Maddocks, K; Porcu, P; Wei, L1
Caballero, MD; Capria, S; Ferrara, F; Galieni, P; Gaudio, F; Gherlinzoni, F; Gobbi, M; Gonella, R; Isidori, A; Loscocco, F; Malerba, L; Meloni, G; Ocio, EM; Rocchi, M; Santoro, A; Specchia, G; Stefani, PM; Visani, G1
Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE1
Cheson, BD; Crawford, J1
Burke, JM; Chen, L; Craig, MD; Flinn, IW; MacDonald, DA; Morganroth, J; Munteanu, MC; van der Jagt, RH1
Abhayankar, S; Aljitawi, O; Diaz, F; Divine, C; Ganguly, S; Iliff, A; McGuirk, J1
Fernandez, SG; Miranda, JJ1
Arcaini, L; Baldini, L; Carella, AM; Cesaretti, M; Goldaniga, M; Luminari, S; Orsucci, L; Pinto, A; Pulsoni, A; Salvi, F; Stelitano, C; Tedeschi, A; Tucci, A1
Aurran, T; Blaise, D; Bouabdallah, R; Broussais, F; Chabannon, C; Coso, D; Garciaz, S; Helvig, A; Schiano de Collela, JM; Stoppa, AM; Xerri, L1
Burke, JM; Craig, M; Flinn, IW; Hawkins, TE; Hertzberg, M; Issa, S; Kahl, BS; Kolibaba, K; MacDonald, D; Munteanu, M; Simpson, D; van der Jagt, RH; Victor, TW; Wood, P1
Cuzzocrea, S; Ferrero, S; Ghione, P; Mauro, E; Mian, M; Mondello, P; Pitini, V; Steiner, N; Visentin, A; Wasle, I; Willenbacher, W; Zaja, F; Zambello, R1
Bouabdallah, K; Cheson, BD; Chua, N; Delwail, V; Dimier, N; Dueck, G; Fingerle-Rowson, G; Fowler, N; Gribben, J; Lennard, A; Lugtenburg, PJ; Mayer, J; Press, O; Salles, G; Sehn, LH; Trněný, M; Wassner-Fritsch, E1
Hamlin, PA1
Munakata, W; Tobinai, K1
Catalano, L; Cerchione, C; De Renzo, A; Della Pepa, R; Di Perna, M; Pane, F; Picardi, M; Pugliese, N1
Cheson, BD; Dimier, N; Gribben, JG; Kimby, E; Launonen, A; Lugtenburg, PJ; Sehn, LH; Thieblemont, C; Trask, PC; Wassner-Fritsch, E1
Alrifai, T; Grant Szymanski, K; Karmali, R; Mahon, B; Okwuosa, T; Venugopal, P1
Cheson, BD2
Carter, NJ; Plosker, GL1
Masiello, D; Tulpule, A1
Wilkes, GM1
Bargetzi, M; Heizmann, M; Kotrubczik, N; Moosmann, P; Wernli, M1
Cheson, BD; Kroll, ML1
D'Andrea, D; Darwish, M; Kahl, B; Melhem, M; Owen, JS; Passarell, JA1
Cheson, BD; Dreyling, M; Friedberg, J; Gribben, J; Hoelzer, D; Knop, S; Montillo, M; Moreau, P; Pieper, A; Rummel, M; Wendtner, CM1
Czuczman, MS; Rummel, MJ1
Czuczman, MS; Elefante, A1
Cheson, BD; Friedberg, JW; Kahl, BS1
Garnock-Jones, KP1
Cheson, BD; Ujjani, C1
Rummel, M1
Montillo, M; Morra, E; Ricci, F; Tedeschi, A; Vismara, E1
Cheson, BD; Friedberg, JW; Kahl, BS; Tremmel, L; Van der Jagt, RH1
Furukawa, Y; Hiraoka, N; Kano, Y; Kikuchi, J; Wada, T1
Caballero, MD; Capria, S; Cuberli, F; Falcioni, S; Ferrara, F; Galieni, P; Gaudio, F; Gherlinzoni, F; Giardini, C; Gobbi, M; Isidori, A; Malerba, L; Meloni, G; Ocio, EM; Rocchi, M; Santoro, A; Sarina, B; Specchia, G; Stefani, PM; Visani, G1
Arranz, R; Calleja, M; Cánovas, A; Cervera, JM; de la Fuente, I; de Oña, R; Domingo, E; Gironella, M; Gorosquieta, A; Grande, C; Guillén, H; Lopez-Lorenzo, JL; Marin, M; Medina, A; Mencha, C; Panizo, C; Peñalver, FJ; Perez, I; Perez, R; Prieto, E; Ramila, E; Salar, A; Sanchez-Gonzalez, B; Sancho, JM; Sebastian, E1
Chan, M; Detroye, A; Ellis, T; Johnson, A; Lesser, GJ; McMullen, K; Mott, R; Renfrow, JJ; Tatter, S1
Balzarotti, M; Bongarzoni, V; Bosi, A; Carpaneto, A; Cortelazzo, S; D'Arco, A; Freilone, R; Gaidano, G; Gobbi, M; Iannitto, E; Liberati, AM; Orciuolo, E; Patti, C; Piccin, A; Puccini, B; Rigacci, L; Rota-Scalabrini, D; Storti, S; Zaja, F; Zinzani, PL1
Asaka, M; Imamura, M; Miyashita, N; Ogasawara, R; Tanaka, J; Tsutsumi, Y1
Bighin, C; Del Mastro, L; Gardin, G; Giraudi, S; Lambertini, M; Levaggi, A; Pronzato, P1
Ackler, S; Boghaert, ER; Chen, J; Clarin, J; Foster, K; Jin, S; Leverson, JD; Mitten, MJ; Phillips, DC; Schlessinger, S; Wang, B1
Hoy, SM1
Cheson, BD; Diehl, V1
Chow, KU; Hoelzer, D; Mitrou, PS; Rummel, MJ; Weidmann, E1
Hoelzer, D; Mitrou, PS; Rummel, MJ1
Hoelzer, D; Kim, SZ; Mitrou, PS; Rost, A; Schuppert, H; Seipelt, G; Weidmann, E1
Bremer, K1
Al-Batran, SE; Chow, KU; Dürk, H; Hansmann, ML; Hecker, R; Hoelzer, D; Josten, KM; Kim, SZ; Kofahl-Krause, D; Mitrou, PS; Neise, M; Rost, A; Rummel, MJ; von Grünhagen, U; Welslau, M1
Arzberger, H; Boewer, C; Bremer, K; Dachselt, K; Franke, A; Freund, M; Fricke, HJ; Hahnfeld, S; Herold, M; Ismer, B; Klinkenstein, C; Müller, C; Niederwieser, D; Pasold, R; Richter, P; Schirmer, V; Schulze, A; Schulze, M; Schwarzer, A; Weniger, J; Winkelmann, C1
Bertoni, F; Zucca, E1
Aldaoud, A; Dreyling, M; Haak, U; Hess, G; Heymanns, J; Hiddemann, W; Huber, C; Köppler, H; Losem, C; Schmitz, S; Thomalla, J; Unterhalt, M; Weide, R1
Friedberg, JW; Hagemeister, FB; Leonard, JP; Levine, AM1
Bessudo, A; Camacho, ES; Chen, L; Cheson, BD; Cohen, P; Fayad, LE; Forero-Torres, A; Friedberg, JW; La Casce, AS; Oliver, JW; Robinson, KS; van der Jagt, RH; Williams, ME1
Forero-Torres, A; Saleh, MN1
Balfour, JA; Goa, KL1
Boehrer, S; Chow, KU; Geduldig, K; Hoelzer, D; Krapohl, A; Mitrou, PS; Weidmann, E1
Heider, A; Niederle, N1

Reviews

28 review(s) available for bendamustine hydrochloride and Lymphoma, Non-Hodgkin

ArticleYear
Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.
    Current treatment options in oncology, 2021, 10-25, Volume: 22, Issue:12

    Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Prednisone; Receptors, Chimeric Antigen; Risk Assessment; Rituximab; Stem Cell Transplantation; Vincristine; Waldenstrom Macroglobulinemia

2021
Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin's Lymphoma or Mantle-Cell Lymphoma.
    Acta medica Indonesiana, 2022, Volume: 54, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Prednisone; Randomized Controlled Trials as Topic; Rituximab; Vincristine

2022
Treatment strategies for patients with diffuse large B-cell lymphoma.
    Cancer treatment reviews, 2022, Volume: 110

    Topics: Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Receptors, Chimeric Antigen; Rituximab; Vincristine

2022
Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach.
    European journal of haematology, 2023, Volume: 111, Issue:6

    Topics: Antigens, CD19; Bendamustine Hydrochloride; Cost-Effectiveness Analysis; Humans; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Rituximab

2023
Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
    Expert review of hematology, 2017, Volume: 10, Issue:8

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Comorbidity; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Treatment Outcome

2017
BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA.
    Acta clinica Croatica, 2018, Volume: 57, Issue:3

    Topics: Adult; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Child; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Medication Therapy Management

2018
Rituximab plus bendamustine for the treatment of aggressive non-hodgkin lymphoma patients with severe liver impairment.
    Clinical advances in hematology & oncology : H&O, 2013, Volume: 11, Issue:3

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Liver Diseases; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Rituximab; Treatment Outcome

2013
Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management.
    The oncologist, 2013, Volume: 18, Issue:8

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Cyclophosphamide; Germany; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Practice Guidelines as Topic; Rituximab

2013
Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes.
    Expert review of hematology, 2013, Volume: 6, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Recurrence; Treatment Outcome

2013
Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Humans; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Prognosis

2014
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vincristine

2015
The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
    Expert opinion on drug discovery, 2016, Volume: 11, Issue:11

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Design; Drug Discovery; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Rituximab

2016
Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20.
    Chemotherapy, 2017, Volume: 62, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Rituximab; Stroke Volume; Treatment Outcome

2017
Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma.
    Drugs, 2008, Volume: 68, Issue:18

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Drug Resistance, Neoplasm; Half-Life; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Neoplasm, Residual; Nitrogen Mustard Compounds; Rituximab

2008
Bendamustine therapy in chronic lymphocytic leukemia.
    Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:10

    Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Drug Tolerance; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Neoplasms; Nitrogen Mustard Compounds

2009
Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nitrogen Mustard Compounds

2010
Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2010, May-01, Volume: 67, Issue:9

    Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds

2010
Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
    Drugs, 2010, Sep-10, Volume: 70, Issue:13

    Topics: Animals; Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds

2010
Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
    Expert review of anticancer therapy, 2010, Volume: 10, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds

2010
Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2010, Volume: 8 Suppl 6

    Topics: Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Pyrazines; Radioimmunotherapy; Rituximab; Thalidomide

2010
Bendamustine: new perspective for an old drug in lymphoproliferative disorders.
    Expert review of hematology, 2010, Volume: 3, Issue:2

    Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Nitrogen Mustard Compounds

2010
[Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2011, Volume: 138, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds

2011
Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.
    Drugs, 2012, Oct-01, Volume: 72, Issue:14

    Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nitrogen Mustard Compounds; Randomized Controlled Trials as Topic; Retrospective Studies

2012
Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.
    Seminars in oncology, 2002, Volume: 29, Issue:4 Suppl 13

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase III as Topic; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prednisolone; Prognosis; Remission Induction; Rituximab; Survival Rate; Vincristine

2002
Hematologic malignancies: new developments and future treatments.
    Seminars in oncology, 2002, Volume: 29, Issue:4 Suppl 13

    Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides

2002
Combination treatment approaches and novel therapies for lymphoma.
    Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:8 Suppl 12

    Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cancer Vaccines; Cytokines; Humans; Immunologic Factors; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Stem Cell Transplantation

2007
Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold War.
    Clinical lymphoma & myeloma, 2007, Volume: 8 Suppl 1

    Topics: Alkylating Agents; Antimetabolites; Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds

2007
Bendamustine.
    Drugs, 2001, Volume: 61, Issue:5

    Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Breast Neoplasms; Female; Half-Life; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Nitrogen Mustard Compounds

2001

Trials

31 trial(s) available for bendamustine hydrochloride and Lymphoma, Non-Hodgkin

ArticleYear
Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
    European journal of haematology, 2022, Volume: 109, Issue:2

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Receptors, Chimeric Antigen; Rituximab

2022
Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma.
    Annals of hematology, 2020, Volume: 99, Issue:4

    Topics: Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Busulfan; Combined Modality Therapy; Etoposide; Febrile Neutropenia; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Premedication; Progression-Free Survival; Prospective Studies; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Young Adult

2020
Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Carboplatin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy

2021
Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Rituximab

2021
Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.
    Clinical lymphoma, myeloma & leukemia, 2021, Volume: 21, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Diagnosis, Differential; Disease Management; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Oligopeptides; Prognosis; Recurrence; Retreatment; Rituximab; Treatment Outcome

2021
Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study.
    Chinese medical journal, 2021, May-06, Volume: 134, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; China; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Prospective Studies; Rituximab

2021
A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study).
    British journal of haematology, 2021, Volume: 193, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Rituximab; Survival Rate

2021
Safety and Pharmacokinetics of Bendamustine Rapid-Infusion Formulation.
    Journal of clinical pharmacology, 2017, Volume: 57, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Bendamustine Hydrochloride; Biological Availability; Chemistry, Pharmaceutical; Cross-Over Studies; Female; Humans; Injection Site Reaction; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Therapeutic Equivalency

2017
Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14).
    Leukemia & lymphoma, 2018, Volume: 59, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Biomarkers; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Recurrence; Retreatment; Treatment Outcome; Young Adult

2018
Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 09-01, Volume: 29, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Chemotherapy-Induced Febrile Neutropenia; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Rituximab; Salvage Therapy; Sulfonamides

2018
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 04-20, Volume: 37, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Progression-Free Survival; Proportional Hazards Models; Rituximab; Survival Rate; Vincristine

2019
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
    Annals of hematology, 2013, Volume: 92, Issue:8

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Comorbidity; Dose-Response Relationship, Drug; Drug Eruptions; Fatigue; Female; Heart Diseases; Hematologic Diseases; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Nitrogen Mustard Compounds; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome

2013
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
    Blood, 2014, May-08, Volume: 123, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Fatigue; Female; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Nitrogen Mustard Compounds; Paresthesia; Peripheral Nervous System Diseases; Prednisone; Rituximab; Treatment Outcome; Vincristine; Vomiting

2014
Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
    Hematological oncology, 2015, Volume: 33, Issue:4

    Topics: Aged; Aged, 80 and over; Bendamustine Hydrochloride; Female; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Taiwan

2015
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.
    Blood, 2015, Jan-08, Volume: 125, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Young Adult

2015
Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.
    Blood, 2014, Nov-06, Volume: 124, Issue:19

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Melphalan; Nitrogen Mustard Compounds; Transplantation, Autologous

2014
A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas.
    British journal of haematology, 2015, Volume: 169, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Thalidomide

2015
Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:1

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Electrocardiography; Female; Heart Rate; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Rituximab

2015
A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bone Marrow; Disease Progression; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Remission Induction; Rituximab; Treatment Outcome

2016
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2016, Volume: 16, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Quality of Life; Rituximab; Surveys and Questionnaires; Vincristine

2016
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:8

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Rituximab; Survival Rate

2016
Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
    Annals of hematology, 2017, Volume: 96, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Quality of Life; Rituximab; Treatment Outcome

2017
Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cohort Studies; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome

2010
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
    Blood, 2011, Sep-22, Volume: 118, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous

2011
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prognosis; Remission Induction; Survival Rate; Treatment Outcome

2002
High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Journal of cancer research and clinical oncology, 2002, Volume: 128, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphopenia; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prognosis; Remission Induction; Salvage Therapy; Survival Rate

2002
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, May-20, Volume: 23, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Risk Assessment; Rituximab; Single-Blind Method; Survival Rate; Treatment Outcome

2005
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
    Journal of cancer research and clinical oncology, 2006, Volume: 132, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Prednisone; Survival Analysis; Treatment Outcome; Vincristine

2006
High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
    Leukemia & lymphoma, 2007, Volume: 48, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome

2007
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jan-10, Volume: 26, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Rituximab; Survival Analysis; Treatment Outcome

2008
Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas.
    Anti-cancer drugs, 2001, Volume: 12, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Remission Induction; Survival Analysis

2001

Other Studies

67 other study(ies) available for bendamustine hydrochloride and Lymphoma, Non-Hodgkin

ArticleYear
Indolent T cell lymphoma involving the central nervous system and successfully treated by bendamustine.
    Annals of hematology, 2022, Volume: 101, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Central Nervous System; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Nitrogen Mustard Compounds; Rituximab

2022
Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy.
    Journal of clinical and experimental hematopathology : JCEH, 2022, Jun-28, Volume: 62, Issue:2

    Topics: Agammaglobulinemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoglobulin G; Lymphocyte Count; Lymphoma, Non-Hodgkin; Lymphopenia; Retrospective Studies; Rituximab

2022
Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report.
    Medicine, 2022, Mar-04, Volume: 101, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Gastroscopy; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome; Ultrasonography

2022
Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas.
    Hematological oncology, 2023, Volume: 41, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Rituximab

2023
The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.
    British journal of haematology, 2022, Volume: 199, Issue:2

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Mitogen-Activated Protein Kinase Kinases; Proto-Oncogene Proteins c-akt; Rituximab

2022
[Standard treatment and future perspectives for follicular lymphoma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2022, Volume: 63, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Quality of Life; Rituximab

2022
Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma.
    Annals of hematology, 2023, Volume: 102, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neurolymphomatosis; Rituximab

2023
Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China.
    Cancer, 2023, 02-15, Volume: 129, Issue:4

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chronic Disease; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Rituximab; Treatment Outcome; Young Adult

2023
Bendamustine and rituximab is well-tolerated and efficient in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma in elderly: A single center observational study.
    International journal of cancer, 2023, 05-01, Volume: 152, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Febrile Neutropenia; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Rituximab

2023
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large
    Annals of hematology, 2023, Volume: 102, Issue:7

    Topics: Adolescent; Adult; Bendamustine Hydrochloride; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Receptors, Chimeric Antigen; Retrospective Studies; Rituximab

2023
[Bendamustine plus rituximab as first-line treatment in patients with indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma : a real-world study in China].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2023, Apr-14, Volume: 44, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Rituximab

2023
Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario.
    British journal of haematology, 2023, Volume: 202, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Non-Hodgkin; Ontario; Prednisone; Retrospective Studies; Rituximab; Vincristine

2023
Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab.
    Journal of clinical and experimental hematopathology : JCEH, 2023, 09-28, Volume: 63, Issue:3

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Rituximab

2023
[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2023, Volume: 64, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell- and Tissue-Based Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunoconjugates; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Receptors, Chimeric Antigen; Retrospective Studies; Rituximab

2023
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.
    Leukemia, 2020, Volume: 34, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm, Residual; Progression-Free Survival; Rituximab

2020
Incidence of infectious complications with the combination of bendamustine and an anti-CD20 monoclonal antibody
    Leukemia & lymphoma, 2020, Volume: 61, Issue:2

    Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Incidence; Lymphoma, Non-Hodgkin; Retrospective Studies; Rituximab

2020
Bendamustine plus rituximab: is it a BRIGHT idea?
    Chinese clinical oncology, 2020, Volume: 9, Issue:2

    Topics: Bendamustine Hydrochloride; Disease-Free Survival; Humans; Lymphoma, Non-Hodgkin; Rituximab

2020
Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi.
    Bone marrow transplantation, 2020, Volume: 55, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Rituximab

2020
Risk Factors for Skin Toxicities Associated with Bendamustine-Based Chemotherapy in Patients with Non-Hodgkin Lymphoma.
    Biological & pharmaceutical bulletin, 2020, Oct-01, Volume: 43, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Drug Resistance, Neoplasm; Female; Humans; Incidence; Logistic Models; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Risk Assessment; Risk Factors; Rituximab

2020
Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021, Volume: 29, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Febrile Neutropenia; Female; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Rituximab; Treatment Outcome

2021
Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin's lymphoma.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:13

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Humans; Lymphoma, Non-Hodgkin; Retrospective Studies; Rituximab

2021
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
    British journal of haematology, 2017, Volume: 178, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Disease-Free Survival; Female; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasms, Second Primary; Rituximab; Time Factors; Treatment Outcome

2017
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Case-Control Studies; Cytarabine; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Young Adult

2018
Painless Vulvar Masses as Initial Manifestation of Marginal Zone Lymphoma.
    Journal of lower genital tract disease, 2018, Volume: 22, Issue:1

    Topics: Antigens, CD20; Antineoplastic Agents; Bendamustine Hydrochloride; Biomarkers, Tumor; Biopsy; Female; Histocytochemistry; Humans; Immunohistochemistry; Leukosialin; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Microscopy; Middle Aged; Rituximab; Treatment Outcome; Vulva; Vulvar Neoplasms

2018
Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy.
    Die Pharmazie, 2018, 05-01, Volume: 73, Issue:5

    Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Bendamustine Hydrochloride; Dexamethasone; Female; Granisetron; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Palonosetron; Retrospective Studies; Vomiting

2018
Increased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 01-07, Volume: 68, Issue:2

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cohort Studies; Female; Humans; Infections; Lymphoma, Non-Hodgkin; Male; Multivariate Analysis; Risk Factors

2019
Deleting Malignant B Cells With Second-Generation Anti-CD20 Antibodies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 08-01, Volume: 36, Issue:22

    Topics: Antibodies, Monoclonal, Humanized; B-Lymphocytes; Bendamustine Hydrochloride; Humans; Lymphoma, Non-Hodgkin; Rituximab

2018
Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
    Pharmacological reports : PR, 2019, Volume: 71, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Poland; Recurrence; Retrospective Studies; Rituximab; Salvage Therapy; Transplantation, Autologous

2019
Conjunctival lymphoma.
    BMJ case reports, 2019, Jul-10, Volume: 12, Issue:7

    Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bendamustine Hydrochloride; Conjunctival Neoplasms; Humans; Lymphoma, Non-Hodgkin; Rituximab

2019
Bendamustine for non-Hodgkin lymphoma. Interview by Louise Rishton.
    Expert review of hematology, 2013, Volume: 6, Issue:2

    Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds

2013
Safe and effective treatment of aggressive non-hodgkin lymphoma with rituximab and bendamustine in patients with severe liver impairment.
    Clinical advances in hematology & oncology : H&O, 2013, Volume: 11, Issue:3

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Liver Diseases; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Rituximab; Treatment Outcome

2013
The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Creatinine; Databases, Factual; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Renal Insufficiency; Retrospective Studies; Treatment Outcome

2014
More than skin-deep.
    Cleveland Clinic journal of medicine, 2013, Volume: 80, Issue:10

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Humans; Lymphoma, Non-Hodgkin; Male; Nail Diseases; Nitrogen Mustard Compounds; Oral Ulcer; Paraneoplastic Syndromes; Pemphigus; Rituximab; Weight Loss

2013
Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.
    Journal of medical economics, 2014, Volume: 17, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase III as Topic; Computer Simulation; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; England; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Prednisone; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rituximab; Vincristine; Wales

2014
Bendamustine as monotherapy and in combination regimens for the treatment of chronic lymphocytic leukemia and non-hodgkin lymphoma: a retrospective analysis.
    Chemotherapy, 2013, Volume: 59, Issue:4

    Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Retrospective Studies; Rituximab; Thrombocytopenia

2013
An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Interactions; Female; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Rituximab

2014
Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab a
    Leukemia & lymphoma, 2015, Volume: 56, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Brain-Derived Neurotrophic Factor; Cognition Disorders; Cyclophosphamide; Doxorubicin; Electroencephalography; Fatigue; Female; Humans; Interleukin-6; Lymphoma, Non-Hodgkin; Male; Middle Aged; Outcome Assessment, Health Care; Prednisone; Rituximab; Surveys and Questionnaires; Vincristine

2015
Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Germany; Health Care Surveys; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Rituximab; Young Adult

2015
Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab.
    Annals of hematology, 2014, Volume: 93, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; CD4-Positive T-Lymphocytes; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Rituximab; Treatment Outcome

2014
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:8

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine

2014
A Second Anti-CD20 Drug for NHL.
    Cancer discovery, 2015, Volume: 5, Issue:7

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Lymphoma, Non-Hodgkin; Treatment Outcome

2015
Adequacy of peripheral blood stem cell mobilization in patients with relapsed B-cell non-Hodgkin lymphoma treated with bendamustine.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:5

    Topics: Bendamustine Hydrochloride; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Peripheral Blood Stem Cells; Recurrence; Transplantation, Autologous; Treatment Outcome

2016
Bendamustine reactivates latent Epstein-Barr virus.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Herpesvirus 4, Human; Humans; Lymphoma, Non-Hodgkin; Virus Activation; Virus Latency

2016
Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity.
    Bone marrow transplantation, 2016, Volume: 51, Issue:2

    Topics: Adult; Aged; Autografts; Bendamustine Hydrochloride; Female; Humans; Kidney Diseases; Lymphoma, Non-Hodgkin; Male; Middle Aged; Stem Cell Transplantation; Transplantation Conditioning

2016
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
    Annals of hematology, 2016, Volume: 95, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Treatment Outcome; Vincristine

2016
Obinutuzumab plus bendamustine in rituximab-refractory indolent lymphoma.
    The Lancet. Oncology, 2016, Volume: 17, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Non-Hodgkin; Rituximab

2016
Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2017, Volume: 25, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Febrile Neutropenia; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Rituximab

2017
Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
    Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vincristine

2008
Bendamustine (Treanda) for CLL and NHL.
    The Medical letter on drugs and therapeutics, 2008, Nov-17, Volume: 50, Issue:1299

    Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds

2008
Drug essentials. An alkylating agent for CLL and NHL.
    Oncology (Williston Park, N.Y.), 2009, Volume: 23, Issue:4 Suppl Nu

    Topics: Alkylating Agents; Antineoplastic Agents; Bendamustine Hydrochloride; Fatigue; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Patient Education as Topic

2009
Bendamustine induced neurotoxicity.
    Clinical advances in hematology & oncology : H&O, 2009, Volume: 7, Issue:11

    Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Brain; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neurotoxicity Syndromes; Nitrogen Mustard Compounds

2009
Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Bendamustine Hydrochloride; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Time Factors; Treatment Outcome

2010
Clinical Roundtable Monograph: recent advances in NHL. Highlights from the 51st ASH Annual Meeting and Exposition, December 5-8, 2009, New Orleans, Louisiana.
    Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Survival Analysis

2010
Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy.
    Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:5

    Topics: Adenine Nucleotides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bendamustine Hydrochloride; Clofarabine; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Phosphoinositide-3 Kinase Inhibitors; Rituximab; Thalidomide

2010
Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multicenter Studies as Topic; Nausea; Nitrogen Mustard Compounds; Rituximab; Survival Analysis; Treatment Outcome

2010
Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
    Leukemia research, 2012, Volume: 36, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Compassionate Use Trials; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Invasiveness; Nitrogen Mustard Compounds; Retrospective Studies; Spain; Treatment Outcome

2012
Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report.
    Journal of neuro-oncology, 2012, Volume: 107, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Central Nervous System Neoplasms; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds

2012
Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).
    Annals of hematology, 2012, Volume: 91, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chemotherapy, Adjuvant; Female; Foundations; Humans; Italy; Lymphoma, Non-Hodgkin; Male; Medical Oncology; Middle Aged; Multicenter Studies as Topic; Nitrogen Mustard Compounds; Recurrence; Retrospective Studies; Rituximab; Societies, Medical; Survival Analysis; Treatment Failure

2012
HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine.
    International journal of hematology, 2012, Volume: 95, Issue:5

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Hepatitis B; Hepatitis B virus; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Nitrogen Mustard Compounds; Rituximab

2012
Bendamustine: inadequate or outdated data.
    Prescrire international, 2012, Volume: 21, Issue:125

    Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nitrogen Mustard Compounds; Randomized Controlled Trials as Topic

2012
Stevens-Johnson syndrome after treatment with bendamustine.
    Leukemia research, 2012, Volume: 36, Issue:7

    Topics: Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Hepatitis C; Humans; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Stevens-Johnson Syndrome

2012
Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.
    British journal of pharmacology, 2012, Volume: 167, Issue:4

    Topics: Aniline Compounds; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Line, Tumor; Humans; Lymphoma, Non-Hodgkin; Mice; Mice, SCID; Nitrogen Mustard Compounds; Proto-Oncogene Proteins c-bcl-2; Rituximab; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays

2012
Bendamustine in the treatment of hematologic malignancies. Introduction.
    Seminars in oncology, 2002, Volume: 29, Issue:4 Suppl 13

    Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Hematologic Neoplasms; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nitrogen Mustard Compounds

2002
In vitro studies with bendamustine: enhanced activity in combination with rituximab.
    Seminars in oncology, 2002, Volume: 29, Issue:4 Suppl 13

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Carcinoma; Complement System Proteins; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Rituximab; Tumor Cells, Cultured

2002
[A new highly effective therapy of indolent non-Hodgkin lymphomas with bendamustin].
    Onkologie, 2003, Volume: 26, Issue:1

    Topics: Animals; Austria; Bendamustine Hydrochloride; Germany; Humans; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Survival Rate; Treatment Outcome

2003
Bendamustine in lymphomas: more to combine?
    Leukemia & lymphoma, 2007, Volume: 48, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Treatment Outcome

2007
In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine.
    Haematologica, 2001, Volume: 86, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Drug Interactions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Tumor Cells, Cultured

2001